العلاج المساعد لميلانوما الجلد المُستأصلة في المرحلة الرابعة

References

DOI: 10.1200/JCO.23.01136

• Patients with resected stage IV melanoma should be offered adjuvant therapy (Type: Informal consensus; Evidence quality: Moderate; Strength of recommendation: Strong).
• Reasonable options for therapy are: nivolumab alone (Evidence quality: Moderate), nivolumab plus ipilimumab followed by nivolumab (Evidence quality: Low), pembrolizumab alone (Evidence quality: Low), and dabrafenib plus trametinib (in patients with BRAF V600E/K disease; Evidence quality: Low).
• Nivolumab 1 mg/kg iv plus ipilimumab 3 mg/kg iv once every 3 weeks for four doses, followed by nivolumab 3mg/kg once every 2 weeks for 1 year or until disease recurrence, whichever comes first (IMMUNED trial).